119 related articles for article (PubMed ID: 36739175)
21. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
22. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S
Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib and cyclophosphamide based chemo-mobilization in multiple myeloma.
Bagal B; Gokarn A; Punatar S; Das S; Bonda A; Nayak L; Chichra A; Kannan S; Mathew LJ; Tembhare P; Patkar N; Poojary M; Ojha S; Subramanian PG; Gujral S; Khattry N
Int J Hematol; 2020 Dec; 112(6):835-840. PubMed ID: 32876851
[TBL] [Abstract][Full Text] [Related]
24. Recombinant human thrombopoietin improves the efficacy of intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor in mobilizing peripheral blood stem cells in patients with multiple myeloma: A cohort study.
Wang G; Chen W; Wu Y; Li Y; Leng Y; Liu A
Medicine (Baltimore); 2017 Dec; 96(50):e9302. PubMed ID: 29390394
[TBL] [Abstract][Full Text] [Related]
25. Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma.
Gettys SC; Gulbis A; Wilhelm K; Sasaki K; Dinh Y; Rondon G; Qazilbash MH
Eur J Haematol; 2017 Apr; 98(4):388-392. PubMed ID: 28009447
[TBL] [Abstract][Full Text] [Related]
26. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of prophylactic antibiotics for the prevention of neutropenic fever in patients with multiple myeloma receiving high-dose cyclophosphamide for stem cell mobilization.
Hou LQ; Liu JR; Gu JL; Chen ML; Kuang LF; Huang BH; Zou WY; Li J
Ann Hematol; 2024 May; 103(5):1601-1611. PubMed ID: 38267561
[TBL] [Abstract][Full Text] [Related]
28. Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.
Niesvizky R; Mark TM; Ward M; Jayabalan DS; Pearse RN; Manco M; Stern J; Christos PJ; Mathews L; Shore TB; Zafar F; Pekle K; Xiang Z; Ely S; Skerret D; Chen-Kiang S; Coleman M; Lane ME
Clin Cancer Res; 2013 Mar; 19(6):1534-46. PubMed ID: 23357980
[TBL] [Abstract][Full Text] [Related]
29. The effect of gradual increment in rhG-CSF dose on stem cell yields in patients with multiple myeloma mobilized with intermediate dose cyclophosphamide plus rhG-CSF.
Hacıoğlu S; Sarı I; Doğu MH; Keskin A
Transfus Apher Sci; 2014 Feb; 50(1):71-4. PubMed ID: 24342458
[TBL] [Abstract][Full Text] [Related]
30. Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m2 of CY.
Weaver CH; Schwartzberg LS; Zhen B; Franco C; Moore M; Smith R; White L; Van Amburg A; Hazelton B; Buckner CD
Bone Marrow Transplant; 1999 Mar; 23(5):421-5. PubMed ID: 10100554
[TBL] [Abstract][Full Text] [Related]
31. Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
Baertsch MA; Schlenzka J; Lisenko K; Krzykalla J; Becker N; Weisel K; Noppeney R; Martin H; Lindemann HW; Haenel M; Nogai A; Scheid C; Salwender H; Fenk R; Graeven U; Reimer P; Schmidt-Hieber M; Goerner M; Schmidt-Wolf IGH; Klein S; Ho AD; Goldschmidt H; Wuchter P
Eur J Haematol; 2017 Jul; 99(1):42-50. PubMed ID: 28370401
[TBL] [Abstract][Full Text] [Related]
32. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma.
Jantunen E; Putkonen M; Nousiainen T; Pelliniemi TT; Mahlamäki E; Remes K
Bone Marrow Transplant; 2003 Mar; 31(5):347-51. PubMed ID: 12634725
[TBL] [Abstract][Full Text] [Related]
33. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.
Skopec B; Skerget M; Zontar D; Zadnik V; Zver S
Wien Klin Wochenschr; 2017 Aug; 129(15-16):545-551. PubMed ID: 28439700
[TBL] [Abstract][Full Text] [Related]
34. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.
Desikan KR; Barlogie B; Jagannath S; Vesole DH; Siegel D; Fassas A; Munshi N; Singhal S; Mehta J; Tindle S; Nelson J; Bracy D; Mattox S; Tricot G
J Clin Oncol; 1998 Apr; 16(4):1547-53. PubMed ID: 9552064
[TBL] [Abstract][Full Text] [Related]
35. Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF.
Jang JE; Cheong JW; Kim SJ; Cho H; Suh C; Lee H; Eom HS; Yhim HY; Lee WS; Min CK; Lee JH; Park JS; Kim JS
Leuk Lymphoma; 2016; 57(6):1389-97. PubMed ID: 26428939
[TBL] [Abstract][Full Text] [Related]
36. Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment.
Clark AD; Douglas KW; Mitchell LD; McQuaker IG; Parker AN; Tansey PJ; Franklin IM; Cook G
Br J Haematol; 2002 Jun; 117(3):605-12. PubMed ID: 12028028
[TBL] [Abstract][Full Text] [Related]
37. The possible cost effectiveness of peripheral blood stem cell mobilization with cyclophosphamide and the late addition of G-CSF.
Min YJ; Kim SW; Suh C; Park J; Kim HJ; Kim JG; Kim TW; Lee JH; Kim SB; Lee KH; Lee JS; Kim WK; Kim SH
J Korean Med Sci; 2000 Feb; 15(1):49-52. PubMed ID: 10719808
[TBL] [Abstract][Full Text] [Related]
38. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Poenisch W; Plötze M; Holzvogt B; Andrea M; Schliwa T; Zehrfeld T; Hammerschmidt D; Schwarz M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Gutsche K; Reifenrath K; Schwarzbach H; Heyn S; Franke GN; Jentzsch M; Leiblein S; Schwind S; Lange T; Vucinic V; AlAli HK; Niederwieser D
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2013-22. PubMed ID: 25976868
[TBL] [Abstract][Full Text] [Related]
39. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
Chhabra S; Callander N; Watts NL; Costa LJ; Thapa B; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Anderson LD; Bal S; Dhakal B; Nathwani N; Shah N; Medvedova E; Bumma N; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Schmidt T; Orlowski RZ; Shain KH; Cowan AJ; Dholaria B; Cornell RF; Jerkins JH; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG; Voorhees PM
Transplant Cell Ther; 2023 Mar; 29(3):174.e1-174.e10. PubMed ID: 36494017
[TBL] [Abstract][Full Text] [Related]
40. Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction.
Abid MB; De Mel S; Abid MA; Yap ES; Gopalakrishnan SK; Chen Y; Yuen YC; Wong HC; Lin A; Poon LM; Koh LP; Chng WJ; Tan LK
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):174-179. PubMed ID: 29398647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
